Platelet-derived Biomaterial
Platelet-derived Biomaterial - Related Videos
08:14
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
0 Views •
Cited by 38 •
2015
Leucocyte-Platelet Rich Fibrin (L-PRF) represents an FDA cleared preparation of autologous platelet concentrates that possesses unique fibrin architecture, enriched platelets and abundant growth factors. Here, we present a protocol for chair-side generation of L-PRF as well as evaluate its mechanical properties including uniaxial testing and suture retention strength testing.
07:44
Overview of Biomaterials
0 Views •
2023
Biomaterials are materials engineered to interact favorably with biological organisms or molecules. These materials can be derived from or produced by an organism, or can even be a synthesized polymer. Engineers use these novel materials in a wide range of applications, such as tissue engineering, biosensing and drug delivery. This video introduces common biologically derived materials, and provides examples of common techniques used to process them. Key challenges in the field are discussed,...
07:58
Electrospinning of Silk Biomaterials
0 Views •
2023
Silk fibers have been processed and used to create fabrics and threads for centuries. However, the solubilizing of silk fibers, thereby turning it into a versatile pre-polymer solution is a much newer technology. Solubilized silk can be processed in many different ways to create a biocompatible material with controllable mechanical properties. This video introduces the processing of silk from silk worm cocoons, and shows how the silk solution can be used to create a fiber mat via...
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
0 Views •
Cited by 5 •
2017
We describe a straightforward method for the isolation of washed platelets from human blood followed by agonist-induced platelet aggregation measurements by turbidimetry. As an example we apply this method for studying the aggregation response of human platelets to collagen after a pre-incubation with the Pannexin1 channel inhibitor Brilliant Blue FCF.
05:07
An In Vitro Method for the Differentiation of Megakaryocytes and Platelet Formation
0 Views •
2025
This video demonstrates a technique for the differentiation of megakaryocytes and the formation of platelets. Hematopoietic stem progenitor cells — isolated from human umbilical cord blood — differentiate into mature megakaryocytes in the presence of thrombopoietin. The mature megakaryocytes produce cytoplasmic extensions termed proplatelets, which give rise to individual platelets.
FAQs
Platelet activation turns the material into a source of signaling molecules: intracellular granules release growth factors and cytokines that can influence inflammation, recruit cells, promote angiogenesis, and support regeneration. This biologic activity explains why platelet-derived preparations are investigated as more than passive fillers, particularly when tissue repair requires coordinated cellular responses.
Plasma proteins contribute structural function by forming fibrin networks. These networks act as a temporary matrix that can retain biologically active components within a repair site while tissue restoration proceeds. Thus, platelet-derived materials can combine signaling from released factors with provisional physical support, a distinction important when designing gels or composite scaffolds.
Composition and clinical performance may vary with preparation methods. Differences in whether a product uses platelet-rich plasma, platelet lysate, fibrin gel, or a composite scaffold can alter the balance between released signaling molecules and structural support. This variability matters when comparing studies or interpreting outcomes, because materials described under the same broad category may not be biologically equivalent.
Supported formulations include platelet-rich plasma, platelet lysate, fibrin gels, and composite scaffolds. These formats present platelet-derived components in different material arrangements, including preparations centered on released factors, temporary gel matrices, or combined structural systems. The formulation connects material design with the intended repair setting and influences how the biomaterial can be used in medicine.
Their uses include wound healing, bone and cartilage repair, drug delivery, and tissue engineering. These applications reflect two complementary capabilities: released platelet signals can influence repair-related cellular behavior, while fibrin or scaffold components can provide temporary structure. In medicine, the same source material can therefore be adapted to different regenerative goals rather than serving only one tissue type.
Preparation methods can change both composition and clinical performance. A study using platelet-rich plasma may not evaluate the same biological or structural profile as one using platelet lysate, a fibrin gel, or a composite scaffold. Comparing results therefore requires attention to the formulation, because the broad label does not guarantee identical material properties or therapeutic effects.